MAIA Biotechnology, Inc. Accounts Payable
MAIA Biotechnology, Inc. (MAIA) had Accounts Payable of $2.84 million as of 2026-06-30, per its 10-Q filed 2026-08-10.
Financial Statements › Balance Sheet › Liabilities › Liabilities, Current › Accounts Payable and Accrued Liabilities, Current
us-gaap:AccountsPayableCurrent · last filed 2026-08-10
- 2026-06-30: Accounts Payable, Current $2.84M.
- 2026-03-31: Accounts Payable, Current $2.98M.
- 2025-12-31: Accounts Payable, Current $2.04M.
- 2025-09-30: Accounts Payable, Current $3.18M.
| Period end | Accounts Payable, Current |
|---|---|
| 2026-06-30 | $2.84M 10-Q · filed 2026-08-10 |
| 2026-03-31 | $2.98M 10-Q · filed 2026-05-11 |
| 2025-12-31 | $2.04M 10-Q · filed 2026-08-10 |
| 2025-09-30 | $3.18M 10-Q · filed 2025-11-07 |
| 2025-06-30 | $1.72M 10-Q · filed 2025-08-11 |
| 2025-03-31 | $1.84M 10-Q · filed 2025-05-09 |
| 2024-12-31 | $1.51M 10-K · filed 2026-03-23 |
| 2024-09-30 | $1.15M 10-Q · filed 2024-11-12 |
| 2024-06-30 | $1.26M 10-Q · filed 2024-08-09 |
| 2024-03-31 | $1.87M 10-Q · filed 2024-05-14 |
| 2023-12-31 | $1.64M 10-K · filed 2025-03-21 |
| 2023-09-30 | $1.23M 10-Q · filed 2023-11-07 |
| 2023-06-30 | $1.55M 10-Q · filed 2023-08-08 |
| 2023-03-31 | $1.13M 10-Q · filed 2023-05-08 |
| 2022-12-31 | $1.17M 10-K · filed 2024-03-21 |
| 2022-09-30 | $1.02M 10-Q/A · filed 2023-02-06 |
| 2022-06-30 | $1.04M 10-Q · filed 2022-08-22 |
| 2021-12-31 | $960.40K 10-K · filed 2023-03-24 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| iBio, Inc. (IBIO) | United States | $0.077B | -2.94 |
| Valion Bio, Inc. (VBIO) | United States | $0.077B | |
| Adicet Bio, Inc. (ACET) | United States | $0.078B | -0.81 |
| Lifevantage Corp (LFVN) | United States | $0.078B | 15.40 |
| Verrica Pharmaceuticals Inc. (VRCA) | United States | $0.076B | -3.39 |
| OS Therapies Inc (OSTX) | United States | $0.076B | -2.17 |
| Gain Therapeutics, Inc. (GANX) | United States | $0.080B | -4.40 |
| Aldeyra Therapeutics, Inc. (ALDX) | United States | $0.074B | -5.57 |
| Cingulate Inc. (CING) | United States | $0.073B | -2.64 |
| Spero Therapeutics, Inc. (SPRO) | United States | $0.073B | 17.41 |